Biosceptre

Biosceptre is pleased to announce that an agreement has been signed with pre-clinical CAR T development company, Carina Biotech, that will see the advancement of a promising cancer immunotherapy.

Biosceptre Acting Chair Sir Greg Winter wins Nobel prize, refines focus to Science Advisory Board and cedes to new Chair Andrew Walton-Green

Biosceptre has initiated its Phase I clinical trial of the peptide vaccine BIL06v, with the first patient treated at the initial trial site on 16th of August 2018.

The proposed Phase I clinical trial for BIL06v (anti-cancer vaccine) was granted conditional approval by the Bellberry Ethics committee on 21st February 2018.

Biosceptre has received over £8M into its series A raise which will be used to resource the next stage of the companies' development; progression into the clinic of Biosceptre's first systemic products against novel oncology target nfP2X7.

The group fosters collaboration throughout the EU on science of Ion Channels and Immune Response

Biosceptre's appointment of a CMO marks a major milestone in progression to the clinic of its therapeutic anticancer vaccine BIL06v against the novel oncology target nfP2X7.

Biosceptre's proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal antibody therapy) was granted conditional approval by the Bellberry Ethics committee.

Biosceptre has published a clinical study demonstrating that its topical drug BIL010t provides a novel, safe and tolerable topical therapy for BCC in the British Journal of Dermatology (BJD)

Biosceptre is pleased to announce the appointment of its independent Director Sir Gregory Winter as the Chair of the Board of Directors.